Actify Neurotherapies Announces Former COO Of Medexpress As CEO
Leading Next Generation Psychiatry Center Adds Kathy Kaluhiokalani to Executive Team
PRINCETON, N.J., Jan. 10, 2019 /PRNewswire/ -- Actify Neurotherapies, a national group of leading ketamine infusion therapy and next generation mental health treatment centers, is excited to announce the appointment of Kathy Kaluhiokalani as its Chief Executive Officer. Kaluhiokalani, who previously served as COO of MedExpress, will lead Actify's rapid growth and execute its mission to deliver effective care for those struggling with mood and anxiety disorders.
"Since 2011, Actify Neurotherapies, originally as Ketamine Treatment Centers, has established itself as the national leader in making rapid-acting and innovative mental health solutions accessible to those who have been let down by antiquated and fractured traditional psychiatry practices. Kathy's previous experience as Chief Operating Officer in a high growth healthcare company, which went from 60 locations to 200+ locations in 4 years, will accelerate Actify's ability to improve mental health by providing every American with the opportunity to benefit from the most cutting-edge treatments and technologies like ketamine infusion therapy," said Actify Neurotherapies Founder and Chief Medical Officer, Dr. Steven Levine.
The growth of Actify Neurotherapies comes at a vital time, as 16 million Americans every year suffer from depression, and millions more from PTSD, OCD, and other mental health disorders. It is difficult to find care that is available in a timely, affordable, and convenient way, and many current options are marginally effective and can leave sufferers committed to long-term treatment with burdensome and harmful side effects.
"I am honored to join Actify Neurotherapies at an incredibly exciting time. It's a privilege to be part of a fast growing healthcare company that delivers innovative, best-in-class treatment options that are making a meaningful difference in the lives of the many people dealing with mood and anxiety disorders. Actify Neurotherapies is positioned to expand treatment options and add new locations, while providing an exceptional patient experience. I look forward to leading the company's continued expansion, and enabling our team to execute on its mission to deliver evidenced-based, compassion-driven care," said Kaluhiokalani.
Bryan Wolff of Anthos Capital commented: "Kathy is a seasoned healthcare executive who complements Actify's premier medical team. With her help, we look forward to expanding Actify's nationwide footprint and accelerating our effort to provide more effective and accessible mental healthcare."
For more information on Actify Neurotherapies and ketamine for depression treatment, please visit www.ActifyNeuro.com
About Actify Neurotherapies
Providing impact through innovation, Actify Neurotherapies offers ketamine infusion therapy and is the leading national mental health treatment practice in the country. Our psychiatrist physicians, in nine locations, have treated thousands of patients since 2011 using industry leading methods and technology to achieve optimal results. The company is headquartered in Princeton, NJ and backed by Anthos Capital.
SOURCE Actify Neurotherapies
Share this article